What is the Standard of Care for Stage II Melanoma Patients in 2022
AIM at Melanoma hosts this special presentation with guest, Jason J. Luke, MD, FACP, director, Cancer Immunotherapeutics Center, UPMC Hillman Cancer Center, associate professor of medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, who discusses the standard of care for Stage II Melanoma patients in 2022. You can watch the webinar Here.
-FDA Approval of KEYTRUDA for Stage IIB and IIC Melanoma Patients;
-What did the clinical trial show?
-What does the treatment entail?
-Are there other clinical trials for stage 2B and 2C being done right now?
-How do you determine what is the best option for you?
-A dedicated question-and-answer session during the webinar will provide an opportunity for attendees to converse and ask questions about the FDA approval.
View past webinars: https://www.aimatmelanoma.org/....melanoma-learning-ce
-
Category
No comments found